Plain-English translation of NCT05738980 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a treatment called anti-TIM-3 blocked RAK cells — specialized immune cells taken from your own body, modified in the laboratory, and given back to you by infusion. The goal is to help prevent hepatocellular carcinoma (liver cancer) from returning after you've had surgery to remove the tumor. Researchers believe this medication may help your immune system keep cancer from coming back.
Even after surgery successfully removes a liver tumor, cancer can sometimes return. This trial exists to see whether the treatment can reduce that risk and improve long-term outcomes for people with hepatocellular carcinoma.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic for screening and then return around weeks 2–3 for your first immune cell infusion. Blood will be drawn at several time points to grow and prepare your immune cells. You'll receive three cycles of cell infusions over approximately 6 months, with additional procedures like a liver imaging treatment (TACE) scheduled in between. After completing the three treatment cycles, you'll be monitored to track whether your cancer returns.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Sponsor
Beijing Hospital
Enrollment target
~88 participants
Started
February 2023
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Caixia Liu, master
Beijing Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.